OPKO Health (OPK) News Today

OPKO Health, Inc. (NASDAQ: OPK) shares have rallied and reached a new 52-week high as investors respond to a major BioReference transaction and a bullish analyst upgrade.

• Positive Sentiment: Labcorp deal provides substantial cash proceeds: Labcorp agreed to acquire select assets of OPKO’s BioReference Health business for $722 million in cash, with a potential earnout of up to $150 million, bringing the possible total value to $872 million. The assets include specialty testing focused on women’s health and the 4Kscore prostate-cancer risk test. Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health
• Positive Sentiment: Strategic shift toward biopharmaceuticals: The divestiture is expected to give OPKO greater financial flexibility and allow management to concentrate on its biopharmaceutical operations. The agreement may also expand patient and provider access to the 4Kscore Test through Labcorp’s nationwide laboratory network. OPKO Health to Sell Select BioReference Assets to Labcorp for $722M
• Positive Sentiment: Analyst upgrade adds momentum: Barrington Research raised OPKO from “Market Perform” to “Outperform” and assigned a $2.25 price target, implying substantial upside from the stock’s recent trading level. Barrington Upgrades OPKO Health to Outperform
• Neutral Sentiment: Shares reached a 52-week high of $1.75: The milestone reflects strong investor interest following the asset-sale announcement, although the stock remains below the new analyst target and could experience volatility after the sharp move.
• Negative Sentiment: Execution and business-mix risks remain: OPKO is selling part of its diagnostics platform, which could reduce ongoing BioReference revenue and earnings contribution. The additional $150 million earnout is contingent, and the transaction must close as planned before OPKO realizes the full expected benefit.